Baird Medical Investment Holdings Limited
NASDAQ:BDMD · NASDAQ Capital Market
-$0.09 today
Vol 0.08M · Avg 0.37M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.0%
avg 54.0%
ROIC
-50.5%
avg 33.8%
ROA
-39.1%
avg 7.2%
Analysis
ROA is currently the strongest return metric at -39.1% versus its period average of 7.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Haimei Wu | Chairwoman of the Board of Directors & Chief Executive Officer | $57,729.00 | — | 44 | $18.20M | 44.40% |
Quan Qiu | Chief Administrative Officer & Executive Director | $51,528.00 | — | 33 | $0.00 | <0.01% |
Wei Hou | Executive Director | $43,998.00 | — | 56 | $91,545.00 | 0.22% |
Jie Li | Acting Chief Financial Officer | — | — | 38 | $0.00 | <0.01% |
Mark S. Saxton | Chief Executive Officer U.S. Subsidiary | — | — | 61 | — | — |
Rongjian Lu | Chief Technology Officer & Deputy GM | — | — | 59 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -25.4% | N/A — |
| Revenue | N/A | N/A | +20.2% | N/A — |
| Net Income | N/A | N/A | +14.1% | N/A — |
| EBIT | N/A | N/A | +6.3% | N/A — |
Analysis
Recent growth has been strongest in Revenue at +20.2% over three years.
Competitors
Peer companies in the same sector
Biodesix, Inc.
NASDAQ:BDSX
$122.59M
electroCore, Inc.
NASDAQ:ECOR
$85.03M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$57.43M
FibroGen, Inc.
FGEN
$36.69M
NeuroOne Medical Technologies Corporation
NMTC
$27.93M
HeartBeam, Inc.
BEAT
$26.10M
Cytosorbents Corporation
CTSO
$25.11M
IceCure Medical Ltd
ICCM
$5.38M
Vicarious Surgical Inc.
RBOT
$3.30M
Inotiv, Inc.
NOTV
$2.79M
Who manages BDMD?
Baird Medical Investment Holdings Limited (BDMD) lists 6 active executives. The top listed executive is Haimei Wu, Chairwoman of the Board of Directors & Chief Executive Officer.
Are BDMD insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.